The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Open accessAbstract
Background and objectives: The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. Design, setting, participants, & measurements: This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m 2 . Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward). Results: Esaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P <0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P <0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. Conclusions: Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hyperkalemia (potassium > 6.0 or 5.5 mmol/l) occurred in 9% of the study population treated with esaxerenone.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [166]
In the citing paper
“Similar to fi nerenone, another nonsteroidal MRA, esaxerenone, has also been shown to lower albumin excretion.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [166]
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [166]
In the citing paper
“In outcomes that only included the smaller trials, 166,167,175 methodological limitations due to uncertainty in reporting of allocation concealment were evident.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [166]
In the citing paper
“However, the long-term kidney and cardiovascular bene fi ts of esaxerenone have not been established, and regulatory approval for esaxerenone is not widespread.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [166]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)
(2014) · Hypertension Research · doi:10.1038/hr.2014.20 · Cited by 1,049
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s79 · Cited by 1,042
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459 · cited 2×
“(27), who showed that eplerenone 50 and 100 mg coadministered with enalapril reduced UACR by 41% and 48%, respectively.”
BackgroundHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationEffects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., & Navis, G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060693 · Cited by 372 · cited 2×
“Because lowering sodium intake or adding a thiazide diuretic to treatment can potentiate an antiproteinuric effect in response to an RASi (29), sodium depletion may be one Baseline 3.”
BackgroundBianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338 · cited 3×
“This was a 12-week trial on the basis of previous trials of eplerenone and spironolactone to ensure sufficient time for the efficacy evaluation to be performed after the decrease in UACR had reached a steady state (19,20).”
Method
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
“placebo.(3) Differences in clinical effects between nonsteroidal MRAs, such as BP and hyperkalaemia, appear to exist based on indirect comparisons, but definitive conclusions cannot be made without head-to-head studies.”
BackgroundDiabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Barrera-Chimal, J., Lima-Posada, I., Bakris, G. L., & Jaisser, F. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00490-8 · Cited by 252
Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06870520 · Cited by 234
Self-citationIto, S., Itoh, H., Rakugi, H., Okuda, Y., Yoshimura, M., & Yamakawa, S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13569 · Cited by 197
Self-citationUpdate on diagnosis, pathophysiology, and management of diabetic kidney disease
Sugahara, M., Pak, W. L. W., Tanaka, T., Tang, S. C. W., & Nangaku, M. (2021) · Nephrology · doi:10.1111/nep.13860 · Cited by 171
Self-citationChaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
“ings from completed or ongoing phase 3 studies are not yet available (Table 1).(77,78) By contrast, five phase 2 studies of finerenone have been published: minerAlocorticoid Receptor antagonist Tolerability Study (ARTS), ARTS-Diabetic Nephropathy (DN), ARTS-DN Japan, ARTS-”
BackgroundWada, T., Inagaki, M., Yoshinari, T., Terata, R., Totsuka, N., Gotou, M., & Hashimoto, G. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01963-z · Cited by 97
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 93
Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors
Azushima, K., Morisawa, N., Tamura, K., & Nishiyama, A. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-1028-6 · Cited by 79
Rakugi, H., Ito, S., Itoh, H., Okuda, Y., & Yamakawa, S. (2019) · Hypertension Research · doi:10.1038/s41440-019-0314-7 · Cited by 73
Self-citationChung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Ortíz, A., Ferro, C. J., Balafa, O. C., Burnier, M., Ekart, R., Halimi, J., Kreutz, R. H., Mark, P. B., Persu, A., Rossignol, P., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab167 · Cited by 69
Satoh, F., Ito, S., Itoh, H., Rakugi, H., Shibata, H., Ichihara, A., Omura, M., Takahashi, K., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00570-5 · Cited by 60
Self-citationWan, N., Rahman, A., & Nishiyama, A. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0377-6 · Cited by 59
Peng, L., Chen, Y., Shi, S., & Wen, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02696-w · Cited by 61
“Recently, the novel mineralocorticoid receptor antagonists (MRAs), such as finerenone [46] and esaxerenone [47], have attracted much attention for intensifying the RAAS inhibition.”
BackgroundRole of mineralocorticoid receptor antagonists in kidney diseases
PATEL, V. G., Joharapurkar, A. A., & Jain, M. R. (2020) · Drug Development Research · doi:10.1002/ddr.21760 · Cited by 65
“In the same clinical trial, the effect of esaxerenone on reduc- ing blood pressure was regardless of baseline blood pressure and eGFR (Ito et al., 2019; Itoh et al., 2019).”
BackgroundInfluentialAntihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Ito, S., Itoh, H., Rakugi, H., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00585-y · Cited by 56
Self-citationShubrook, J. H., Neumiller, J. J., & Wright, E. E. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2009726 · Cited by 61
“on mortality and ESKD are unknown [72].”
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Mullen, N., Curneen, J. M. G., Donlon, P. T., Prakash, P., Bancos, I., Gurnell, M., & Dennedy, M. C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad026 · Cited by 56
Barrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
“Studies of esaxerenone showed that trough plasma levels increased dose-dependently in patients with hypertension and moderate renal impairment (irrespective of stratification by baseline eGFR) [46] or with type 2 diabetes and microalbuminuria [47].”
BackgroundAldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 48
Rakugi, H., Yamakawa, S., & Sugimoto, K. (2020) · Hypertension Research · doi:10.1038/s41440-020-00569-y · Cited by 49
“J204 was a randomized, double-blind, placebocontrolled, phase II clinical study in patients with type 2 diabetes with microalbuminuria.”
BackgroundInfluentialLuo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 44
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., & Tanabe, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754239 · Cited by 45
“5, and 5 mg daily) significantly reduced albuminuria in a dose-dependent manner (Ito et al., 2019).”
BackgroundThe Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury
Ayuzawa, N., & Fujita, T. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020071041 · Cited by 45
The mineralocorticoid receptor in chronic kidney disease
Barrera‐Chimal, J., Jaisser, F., & Anders, H. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15734 · Cited by 42
Lerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
“25 to 5 mg/day of esaxerenone to a RAS inhibitor compared with placebo at 3 months relative to baseline [68].”
BackgroundWhitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 49
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, J. P., Pitt, B., & Zannad, F. M. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011629 · Cited by 47
“77,96,97 The one that has undergone the most extensive clinical evaluation is finerenone.”
Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02075-y · Cited by 41
Self-citationMende, C. W., Samarakoon, R., & Higgins, P. J. (2023) · American Journal of Nephrology · doi:10.1159/000528783 · Cited by 39
Kidney Allograft Fibrosis: Diagnostic and Therapeutic Strategies
Saritas, T., & Kramann, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003678 · Cited by 32
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Hojs, N. V., Bevc, S., Ekart, R., Piko, N., Petreski, T., & Hojs, R. (2021) · Pharmaceuticals · doi:10.3390/ph14060561 · Cited by 30
Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease—From Bench to Bedside
Nicholas, S. B. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.010 · Cited by 27
Nakamura, T., & Kawaguchi, A. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.855 · Cited by 24
Gu, X., Zhang, S., & Zhang, T. (2021) · Cells · doi:10.3390/cells10040869 · Cited by 25
Rahman, A., Sawano, T., Sen, A., Hossain, A., Jahan, N., Kobara, H., Masaki, T., Kosaka, S., Kitada, K., Nakano, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042069 · Cited by 21
“Several basic and clinical studies have already demonstrated the tolerability and suitability of esaxerenone in patients with essential hypertension [16,17] or in those with hypertension and type 2 diabetes [18,19].”
BackgroundRossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
Aldosterone: Renal Action and Physiological Effects
Johnston, J. G., Welch, A., Cain, B. D., Sayeski, P. P., Gumz, M. L., & Wingo, C. S. (2023) · Comprehensive physiology · doi:10.1002/cphy.c190043 · Cited by 49
Novel Therapies for Kidney Disease in People With Diabetes
Khurana, N., James, S., Coughlan, M. T., MacIsaac, R. J., & Ekinci, E. I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab639 · Cited by 23
Rossing, P. R., Persson, F., Frimodt‐Møller, M., & Hansen, T. W. (2020) · Diabetes · doi:10.2337/dbi19-0038 · Cited by 23
“Esaxerenone and finerenone were demonstrated to reduce microalbuminuria in type 2 diabetes (56,57).”
BackgroundWish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 24
“gov identifier: NCT02345057).(99) Incidences of hyperkalemia observed with up to 2.”
BackgroundArai, K., Morikawa, Y., Ubukata, N., & Sugimoto, K. (2020) · Hypertension Research · doi:10.1038/s41440-020-0495-0 · Cited by 18
“In fact, recent clinical studies have indicated that adding esaxerenone to an RAS inhibitor enhances both antihypertensive and antialbuminuric effects compared with the effects of an RAS inhibitor alone [13, 18, 19].”
BackgroundOkuda, Y., Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Sawanobori, T., & Taguri, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-01008-w · Cited by 18
“previous paper [13], sodium depletion may be one possible”
BackgroundSelf-citationRecent advances in the management of secondary hypertension: chronic kidney disease
Masuda, T., & Nagata, D. (2020) · Hypertension Research · doi:10.1038/s41440-020-0491-4 · Cited by 19
Jiang, X., Zhang, Z., Li, C., Zhang, S., Su, Q., Yang, S., Liu, X., Hu, Y., & Pu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896947 · Cited by 22
“Five RCTs (Bakris et al., 2015; Ito et al., 2019; Bakris et al., 2020; Ito et al., 2020; Pitt et al., 2021) reported the incidence of hyperkalemia involving finerenone and esaxerenone, as shown in Figure 6.”
BackgroundMethodInfluentialNetwork meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Wu, Y., Lin, H., Tao, Y., Xu, Y., Chen, J., Jia, Y., & Zheng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967317 · Cited by 19
“For several nonsteroid MRAs, however, eGFR decreased after the administration of MRAs and returned to baseline during the follow-up period, which suggested that no severe damage was caused by drug administration (Ito et al., 2019;Wada et al., 2021).”
BackgroundShaikh, A., Ray, J., & Campbell, K. N. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s325916 · Cited by 18
“Finerenone has distinct pharmacologic characteristics that differentiate it from steroidal MRAs.”
BackgroundInfluentialMineralocorticoid receptor antagonists in cardiovascular translational biology
CHILTON, R. J., & Silva‐Cardoso, J. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000289 · Cited by 17
Solis‐Herrera, C., & Triplitt, C. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15327 · Cited by 18
Young, M. J., Kanki, M., Karthigan, N., & Konstandopoulos, P. (2021) · Endocrinology · doi:10.1210/endocr/bqab105 · Cited by 16
Yamada, M., Ishizuka, T., Inoue, S., Rozehnal, V., Fischer, T., & Sugiyama, D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090928 · Cited by 15
“In clinical settings, esaxerenone reduces blood pressure in patients with hypertension in a dosedependent manner (Ito et al., 2019a, 2020), and the effect persists for 52 weeks in patients with insufficient hypotensive effect by reninangiotensin system inhibitors and calcium channel blocker (Rakugi…”
BackgroundCardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
“68 In the small, short-term (14 days) phase II ARTS study in HFrEF patients, finerenone was associated with a dose-dependent decrease in eGFR up to − 3.6 mL/min/1.73 m 2 , which was smaller as compared with the decrease observed with spironolactone ( − 6.7 mL/min/1.73 m 2 ).”
BackgroundInfluentialBădilă, E. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.487 · Cited by 15
“placebo; rate of discontinuation due to hyperkalemia was dosedependent, reaching 10% for the 5 mg/day esaxerenone (20).”
BackgroundЈаnkovic, S., & Janković, S. V. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00760-1 · Cited by 17
“A second-phase, randomized, double-blind, placebocontrolled clinical trial (NCT02345057; JapiCTI-152774) investigated the efficacy and safety of esaxerenone added to renin–angiotensin inhibitor therapy in Japanese patients with type 2 diabetes mellitus accompanied by microalbuminuria (urinary albumin/creatinine ratio…”
MethodThe nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
Gillard, P., Schnell, O., & Groop, P. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108462 · Cited by 14
Targeting renal damage: The ACE2/Ang-(1–7)/mas axis in chronic kidney disease
Zheng, J., & Hao, H. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111413 · Cited by 17
Barrera‐Chimal, J., Gerarduzzi, C., Rossignol, P., & Jaisser, F. (2022) · Clinical Science · doi:10.1042/cs20220212 · Cited by 19
“(75-77) A major challenge will be the uptake and implementation of novel therapeutic options into the daily clinical practice in CKD patients.”
BackgroundMorita, R., Tsukamoto, S., Obata, S., Yamada, T., Uneda, K., Uehara, T., Rehman, M. E., Azushima, K., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14976 · Cited by 16
Chen, Q., Wei, G., Wang, Y., Li, X., Zhao, Q., Zhu, L., Xiao, Q., & Xiong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1338044 · Cited by 11
Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 12
“, 2019 [91] Double-blind, parallel-group RCT 12 weeks 365 T2DM, UACR 45–300 mg/g, eGFR ≥ 30 mL/min/1.”
Kario, K., Ohishi, M., Katsuya, T., Taguchi, T., Tanabe, A., Sugimoto, K., & Shimosawa, T. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14705 · Cited by 12
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Lo, K. B., Rangaswami, J., & Vaduganathan, M. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac322 · Cited by 15
Sato, A., & Nishimoto, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00940-1 · Cited by 11
“(urinary albumin–creatinine ratio 45–300 mg/g Cr, eGFR >30 mL/min) being treated with RAS inhibitors [51].”
Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators
Koca, D., & Lother, A. (2023) · Steroids · doi:10.1016/j.steroids.2023.109291 · Cited by 12
Yang, S., Zhao, X., Zhang, J., Liu, H., Wang, Y., & Wang, Y.-G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1429261 · Cited by 9
Hirai, T., Ueda, S., Ogura, T., Katayama, K., Dohi, K., Hosohata, K., Aoyama, T., Matsumoto, Y., & Iwamoto, T. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003372 · Cited by 10
“MRAs have been reported to cause hyperkalemia in a dose-dependent manner [6,7].”
BackgroundMontero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 18
Imamura, T., Oshima, A., Narang, N., & Kinugawa, K. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0115 · Cited by 10
Ding, K., Li, Z., Lu, Y., & Sun, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.038 · Cited by 9
Controversies in Hypertension V: Resistant and Refractory Hypertension
Filippone, E. J., Naccarelli, G. V., & Foy, A. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.09.015 · Cited by 13
Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
Rahman, A., Jahan, N., Rahman, M. T., & Nishiyama, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031922 · Cited by 9
Fukata, F., Eriguchi, M., Tamaki, H., Uemura, T., Tasaki, H., Furuyama, R., Nishimoto, M., Kosugi, T., Tanabe, K., Morimoto, K., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02433-y · Cited by 6
PREVENTING DIABETIC KIDNEY DISEASE: A SYSTEMATIC REVIEW OF CURRENT PHARMACOLOGICAL APPROACHES
Dharani, B., SEBASTIAN, S., Nazrin, S., & SUBA, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i1.52956 · Cited by 6
Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
Oshima, A., Imamura, T., Narang, N., & Kinugawa, K. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0024 · Cited by 8
Soe, K. K., & Selvarajah, D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101149 · Cited by 6
“Esaxer-enone, has been shown to lower albumin excretion 89,90 , although its long-term kidney and cardiovascular benefits remain unestablished.”
Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?
Rossing, P. R., Frimodt‐Møller, M., & Persson, F. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151430 · Cited by 5
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease
Watson, K., Kukin, A., Wasik, A., & Shulenberger, C. E. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000990 · Cited by 5
Rossing, P. R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab243 · Cited by 8
Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease
Rossing, P. R. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16201020 · Cited by 6
Alexandrou, M. E., Theodorakopoulou, M. P., Kanbay, M., & Sarafidis, P. A. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-021-00641-1 · Cited by 6
“In a phase II trial in 365 patients with T2DM and a UACR ≥ 45 to <300mg/g already on a RAS-blocker, treatment with esaxerenone showed a dose-dependent reduction of albuminuria compared to placebo, ranging from 38% to 56%, after 12 weeks [88].”
Rossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3
“Die behördliche Zulassung von Esaxerenon ist bislang auf die Behandlung von Bluthochdruck in Japan beschränkt [28, 29].”
Kamrul-Hasan, A. B. M., Mondal, S., Nagendra, L., Dutta, D., Bhattacharya, S., & Pappachan, J. M. (2025) · Medicine · doi:10.1097/md.0000000000043615 · Cited by 3
“Four RCTs had durations of 12 weeks, [21,22,24,25] while the other spanned 52 weeks.”
Yoshihara, K., Fukae, M., Kastrissios, H., Wada, R., & Shimizu, T. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100535 · Cited by 4
Rossing, P. R., & Flyvbjerg, A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch44 · Cited by 3
Novel Treatments and the Future of DKD: What Is on the Horizon?
Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2
Yoshihara, K., Fukae, M., Kastrissios, H., Wada, R., Shimizu, T., & Ishizuka, H. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100516 · Cited by 4
Fan, Q., Qin, G., Du, B., Kan, M., Li, M., Li, Q., & Zhang, Z. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109236 · Cited by 1
Glycemic Control and Future Perspectives for Treatment
Miyamoto, S., & Shikata, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_6 · Cited by 1
Self-citationTailoring the management of hypertension to comorbidities
Mendoza, M. F., Kachur, S. M., & Lavie, C. J. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000860 · Cited by 1
Future of Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Nephropathy
Prkačin, I. (2021) · Cardiologia Croatica · doi:10.15836/ccar2021.157
Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease
王, 璇. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131065
Aktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01235-4
Metadata
- Authors
- Ito, S., Shikata, K., Nangaku, M., Okuda, Y., & Sawanobori, T.
- Affiliations
- Tohoku University (JP)
- Okayama University Hospital (JP)
- The University of Tokyo (JP)
- Biostatistics and Data Management Department, and
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Ito, Sadayoshi
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-06-27
- Volume
- 14
- Issue
- 8
- Pages
- 1161-1172
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC6682830
- OpenAlex
- W2954234894
- Cited by
- 107
- References
- 34
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 24 · 2022: 17 · 2021: 23 · 2020: 19 · 2019: 2
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- esaxerenone, type 2 diabetes, microalbuminuria, diabetic nephropathy, mineralocorticoid receptor antagonists, renin-angiotensin system inhibitors, albumin-creatinine ratio, hyperkalemia, drug safety, Japanese patients, adjunctive therapy, EGFR, hypertension, renin-angiotensin system blockade
- MeSH terms
- Aged, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyrroles, Sulfones, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.